.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,404,675

« Back to Dashboard

Details for Patent: 8,404,675

Title:Benzazepine derivatives and methods of prophylaxis or treatment of 5HT2C receptor associated diseases
Abstract: The present invention relates to certain 1-substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives of Formula (I), that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis or treatment of 5HT2C receptor associated diseases, conditions or disorders, such as, obesity and related disorders.
Inventor(s): Smith; Brian (San Diego, CA), Gilson, III; Charles A. (San Diego, CA), Schultz; Jeffrey (San Diego, CA), Smith; Jeffrey (San Diego, CA)
Assignee: Arena Pharmaceuticals, Inc. (San Diego, CA)
Filing Date:Mar 22, 2010
Application Number:12/729,026
Claims:1. A compound of Formula (I): ##STR00032## wherein: R.sub.1 is H or C.sub.1-8 alkyl; R.sub.2 is C.sub.1-4 alkyl, --CH.sub.2--O--C.sub.1-4 alkyl, C.sub.1-4 haloalkyl or CH.sub.2OH; and R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are each independently H, C.sub.1-4 alkyl, amino, cyano, halogen, C.sub.1-4 haloalkyl, nitro or OH; or a pharmaceutically acceptable salt, or hydrate thereof; provided that when R.sub.2 is C.sub.1-4 alkyl, --CH.sub.2--O--C.sub.1-4 alkyl, and CH.sub.2OH then R.sub.3 and R.sub.6 are not both hydrogen.

2. The compound according to claim 1 wherein R.sub.1 is H.

3. The compound according to claim 1 wherein R.sub.1 is C.sub.1-8 alkyl.

4. The compound according to claim 3 wherein R.sub.1 is methyl.

5. The compound according to claim 3 wherein R.sub.1 is ethyl.

6. The compound according to claim 3 wherein R.sub.1 is n-propyl.

7. The compound according to claim 3 wherein R.sub.1 is iso-propyl.

8. The compound according to claim 3 wherein R.sub.1 is n-butyl.

9. The compound according to claim 1 wherein R.sub.2 is C.sub.1-4 alkyl.

10. The compound according to claim 9 wherein R.sub.2 is methyl.

11. The compound according to claim 9 wherein R.sub.2 is ethyl.

12. The compound according to claim 9 wherein R.sub.2 is iso-propyl.

13. The compound according to claim 9 wherein R.sub.2 is n-butyl.

14. The compound according to claim 1 wherein R.sub.2 is C.sub.1-4 haloalkyl.

15. The compound according to claim 14 wherein R.sub.2 is --CF.sub.3.

16. The compound according to claim 1 wherein R.sub.3 is H.

17. The compound according to claim 1 wherein R.sub.3 is C.sub.1-4 alkyl.

18. The compound according to claim 17 wherein R.sub.3 is --CH.sub.3.

19. The compound according to claim 1 wherein R.sub.3 is amino.

20. The compound according to claim 1 wherein R.sub.3 is cyano.

21. The compound according to claim 1 wherein R.sub.3 is halogen.

22. The compound according to claim 21 wherein R.sub.3 is a fluorine atom.

23. The compound according to claim 21 wherein R.sub.3 is a chlorine atom.

24. The compound according to claim 21 wherein R.sub.3 is a bromine atom.

25. The compound according to claim 21 wherein R.sub.3 is an iodine atom.

26. The compound according to claim 1 wherein R.sub.3 is C.sub.1-4 haloalkyl.

27. The compound according to claim 26 wherein R.sub.3 is CF.sub.3.

28. The compound according to claim 1 wherein R.sub.3 is nitro.

29. The compound according to claim 1 wherein R.sub.3 is --OH.

30. The compound according to claim 1 wherein R.sub.4 is H.

31. The compound according to claim 1 wherein R.sub.4 is C.sub.1-4 alkyl.

32. The compound according to claim 31 wherein R.sub.4 is --CH.sub.3.

33. The compound according to claim 1 wherein R.sub.4 is amino.

34. The compound according to claim 1 wherein R.sub.4 is cyano.

35. The compound according to claim 1 wherein R.sub.4 is halogen.

36. The compound according to claim 35 wherein R.sub.4 is a fluorine atom.

37. The compound according to claim 35 wherein R.sub.4 is a chlorine atom.

38. The compound according to claim 35 wherein R.sub.4 is a bromine atom.

39. The compound according to claim 35 wherein R.sub.4 is an iodine atom.

40. The compound according to claim 1 wherein R.sub.4 is C.sub.1-4 haloalkyl.

41. The compound according to claim 40 wherein R.sub.4 is CF.sub.3.

42. The compound according to claim 1 wherein R.sub.4 is nitro.

43. The compound according to claim 1 wherein R.sub.4 is --OH.

44. The compound according to claim 1 wherein R.sub.5 is H.

45. The compound according to claim 1 wherein R.sub.5 is C.sub.1-4 alkyl.

46. The compound according to claim 45 wherein R.sub.5 is --CH.sub.3.

47. The compound according to claim 1 wherein R.sub.5 is amino.

48. The compound according to claim 1 wherein R.sub.5 is cyano.

49. The compound according to claim 1 wherein R.sub.5 is halogen.

50. The compound according to claim 49 wherein R.sub.5 is a fluorine atom.

51. The compound according to claim 49 wherein R.sub.5 is a chlorine atom.

52. The compound according to claim 49 wherein R.sub.5 is a bromine atom.

53. The compound according to claim 49 wherein R.sub.5 is an iodine atom.

54. The compound according to claim 1 wherein R.sub.5 is C.sub.1-4 haloalkyl.

55. The compound according to claim 54 wherein R.sub.5 is CF.sub.3.

56. The compound according to claim 1 wherein R.sub.5 is nitro.

57. The compound according to claim 1 wherein R.sub.5 is --OH.

58. The compound according to claim 1 wherein R.sub.6 is H.

59. The compound according to claim 1 wherein R.sub.6 is C.sub.1-4 alkyl.

60. The compound according to claim 59 wherein R.sub.6 is --CH.sub.3.

61. The compound according to claim 1 wherein R.sub.6 is amino.

62. The compound according to claim 1 wherein R.sub.6 is cyano.

63. The compound according to claim 1 wherein R.sub.6 is halogen.

64. The compound according to claim 63 wherein R.sub.6 is a fluorine atom.

65. The compound according to claim 63 wherein R.sub.6 is a chlorine atom.

66. The compound according to claim 63 wherein R.sub.6 is a bromine atom.

67. The compound according to claim 63 wherein R.sub.6 is an iodine atom.

68. The compound according to claim 1 wherein R.sub.6 is C.sub.1-4 haloalkyl.

69. The compound according to claim 68 wherein R.sub.6 is CF.sub.3.

70. The compound according to claim 1 wherein R.sub.6 is nitro.

71. The compound according to claim 1 wherein R.sub.6 is --OH.

72. The compound of claim 1 selected from: 6,8-Dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; 6-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; 8-Chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; and 8,9-Dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

73. The compound of claim 1 that is 9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

74. The compound of claim 1 selected from: N-methyl-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; and N-methyl-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

75. The compound according to claim 1 wherein said compound is an R enantiomer.

76. The compound according to claim 1 wherein said compound is an S enantiomer.

77. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

78. A method of treatment of obesity comprising administering to an individual in need of such treatment a therapeutically effective amount of a compound according to claim 1.

79. The method according to claim 78 wherein said individual is a mammal.

80. The method according to claim 79 wherein said mammal is a human.

81. A method of decreasing food intake of an individual comprising administering to said individual a therapeutically effective amount of a compound according to claim 1.

82. The method according to claim 81 wherein said individual is a mammal.

83. The method according to claim 82 wherein said mammal is a human.

84. A method of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount of a compound according to claim 1.

85. The method according to claim 84 wherein said individual is a mammal.

86. The method according to claim 85 wherein said mammal is a human.

87. A method of controlling weight gain of an individual comprising administering to said individual suffering from weight control a therapeutically effective amount of a compound according to claim 1.

88. The method according to claim 87 wherein said individual is a mammal.

89. The method according to claim 88 wherein said mammal is a human.

90. The method according to claim 83 wherein the human has a body mass index of about 18.5 to about 45.

91. The method according to claim 83 wherein the human has a body mass index of about 25 to about 45.

92. The method according to claim 83 wherein the human has a body mass index of about 30 to about 45.

93. The method according to claim 83 wherein the human has a body mass index of about 35 to about 45.

94. A method of producing a pharmaceutical composition comprising admixing at least one compound according to claim 1 and at least one pharmaceutically acceptable carrier.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc